Dermatophytic onychomycosis, also known as tinea unguium, is a fungal disease of toenails or fingernails that causes ring infection over nails. Trichophyton rubrum and trichophyton mentagrophytes are common strains of fungi responsible for causing dermatophytic onychomycosis. Furthermore, yeasts and non-dermatophyte molds are other agents that spread the infection. Public places such as gym, swimming pool, and others that are infected with disease causing fungal agents are major source, which cause dermatophytic onychomycosis. Moreover, continuous use of shoes for a longer duration and contact of toe nail with wet surface causes the fungal infection. Increasing incidences of the infection are evident in sportsperson, owing to continuous use of shoe, sweating at nails, and traumatic nail injuries.
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/dermatophytic-onychomycosis-treatment-market-2053
Major symptoms of dermatophytic onychomycosis include thickening and whitening of nails. Moreover, the nails become brittle and appear white as the infection progresses. People suffering from diabetes, peripheral vascular disease, HIV, immune suppression, obesity, and geriatric population are at increased risk of this common fungal infection. Dermatophytic onychomycosis could be treated with either topical preparations or oral antifungal agents based on the severity of infection. The treatment often lasts for an average period of six months. In recent past, advancement in therapy with the introduction of effective topical and oral products has controlled the rapid spread of dermatophytic onychomycosis.
The global dermatophytic onychomycosis treatment market size was valued at US$ 2,596.8 million in 2017, and is expected to witness a CAGR of 12.6% over the forecast period (2018 – 2026).
Increased global prevalence of dermatophytic onychomycosis is expected to propel growth of the dermatophytic onychomycosis treatment market
Dermatophytic onychomycosis is most common nail disorder. According to a report in the Journal of Cutaneous Medicine and Surgery, 2017, onychomycosis accounts for 50% of all nail diseases and prevalence of onychomycosis was estimated to be 5.5% with margin of error of + 3% worldwide. Prophylactic use of topical antifungal agent is expected to aid in effective treatment of dermatophytic onychomycosis, which in turn is major factor contributing to the market growth.
However, several factors deter growth for the dermatophytic onychomycosis treatment market. For instance, treatment of dermatophytic onychomycosis on an average lasts for 5-6 months and with such long term course, patient’s compliance is a critical problem with dose fatigue and adverse effects on body parts such as liver, kidney, and heart (hepatic, renal impairment).
Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2053
Development of new therapies that aid in treatment of dermatophytic onychomycosis is expected to drive growth of the dermatophytic onychomycosis treatment market over the forecast period
Introduction of new drug candidates and adoption of new treatment approaches is a major factor contributing to the dermatophytic onychomycosis treatment market growth. For instance, in 2014, the U.S. Food and Drug Administration (FDA) approved two new topical antifungal drugs—efinaconazole and tavaborole— for the treatment of dermatophytic onychomycosis caused by Trichophyton rubrum and Trichophyton mentagrophytes. Efinaconazole is the first approved topical triazole antifungal agent and tavaborole is the first approved oxobarole antifungal agent for this indication. These agents offer short treatment courses, high cure rates, and few relapse cases.
Moreover, increasing preference of laser-based therapy for external treatment of dermatophytic onychomycosis is expected to propel the market growth. The treatment is preferred by patients with drug adversity aroused from continuous use of systemic antifungal agents. Furthermore, Ionophresis and photodynamic therapy which are emerging approaches to treat dermatophytic onychomycosis are witnessing significant growth, owing to efforts going on establishing clinical evidence for them.
Key players operating in the dermatophytic onychomycosis treatment market include, Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc., Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and Merz Pharma.
Request For Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/2053
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]
Subscribe to our newsletter to get notification about new updates,information, discount, etc..